GLP-1 agonists in addiction therapy – review
References
- Angarita GA, Matuskey D, Pittman B, Costeines JL, Potenza MN, Jastreboff AM, Schmidt HD, Malison RT. Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder. Drug Alcohol Depend. 2021 Apr 1;221:108614. doi: 10.1016/j.drugalcdep.2021.108614. Epub 2021 Feb 15. PMID: 33621809; PMCID: PMC8026565.
- Beck J, Hasenböhler F, Werlen L, Lengsfeld S, Meienberg A, Bathelt C, Vogt D, Christ-Crain M, Burkard T, Winzeler B. Blood pressure changes during smoking cessation in a randomized, double-blind, placebo-controlled trial of dulaglutide treatment. Eur J Prev Cardiol. 2025 Oct 10;32(14):1394–1402. doi: 10.1093/eurjpc/zwaf055. PMID: 40037282.
- Brunchmann A, Thomsen M, Fink-Jensen A. The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review. Physiol Behav. 2019 Jul 1;206:232–242. doi: 10.1016/j.physbeh.2019.03.029. Epub 2019 Apr 1. PMID: 30946836; PMCID: PMC6520118.
- Chuong V, Farokhnia M, Khom S, Pince CL, Elvig SK, Vlkolinsky R, Marchette RC, Koob GF, Roberto M, Vendruscolo LF, Leggio L. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023 Jun 22;8(12):e170671. doi: 10.1172/jci.insight.170671. PMID: 37192005; PMCID: PMC10371247.
- Eren-Yazicioglu CY, Yigit A, Dogruoz RE, Yapici-Eser H. Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol. Front Behav Neurosci. 2021 Jan 18;14:614884. doi: 10.3389/fnbeh.2020.614884. PMID: 33536884; PMCID: PMC7848227.
- Farr OM, Sofopoulos M, Tsoukas MA, Dincer F, Thakkar B, Sahin-Efe A, Filippaios A, Bowers J, Srnka A, Gavrieli A, Ko BJ, Liakou C, Kanyuch N, Tseleni-Balafouta S, Mantzoros CS. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia. 2016 May;59(5):954–65. doi: 10.1007/s00125-016-3874-y. Epub 2016 Feb 1. PMID: 26831302; PMCID: PMC4826792.
- Farr OM, Upadhyay J, Rutagengwa C, DiPrisco B, Ranta Z, Adra A, Bapatla N, Douglas VP, Douglas KAA, Nolen-Doerr E, Mathew H, Mantzoros CS. Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies. Diabetes Obes Metab. 2019 Nov;21(11):2459–2464. doi: 10.1111/dom.13827. Epub 2019 Aug 8. PMID: 31282006; PMCID: PMC6800581.
- Hendershot CS, Bremmer MP, Paladino MB, Kostantinis G, Gilmore TA, Sullivan NR, Tow AC, Dermody SS, Prince MA, Jordan R, McKee SA, Fletcher PJ, Claus ED, Klein KR. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025 Apr 1;82(4):395–405. doi: 10.1001/jamapsychiatry.2024.4789. PMID: 39937469; PMCID: PMC11822619.
- Husain B, Ray S, Tafuto B. A Systematic Review of Treatment Approaches for Individuals With Coexisting Diabetes and Substance Use Disorder. Cureus. 2025 Oct 24;17(10):e95352. doi: 10.7759/cureus.95352. PMID: 41287656; PMCID: PMC12640742.
- Hviid MEB, Christoffersen LAN, Klausen MK, Brodersen T, Pedersen OB, Ostrowski SR, Larsen MH, Kongstad M, Jensen ME, Vilsbøll T, Fink-Jensen A. Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial. Alcohol Clin Exp Res (Hoboken). 2025 Aug;49(8):1659–1666. doi: 10.1111/acer.70110. Epub 2025 Jul 9. PMID: 40630018; PMCID: PMC12365570.
- Jensen ME, Klausen MK, Bergmann ML, Knudsen GM, Vilsbøll T, Stove C, Fink-Jensen A. Blood phosphatidylethanol measurements indicate GLP-1 receptor stimulation causes delayed decreases in alcohol consumption. Alcohol Clin Exp Res (Hoboken). 2025 May;49(5):1161–1165. doi: 10.1111/acer.70041. Epub 2025 Mar 23. PMID: 40123107; PMCID: PMC12098802.
- Klausen MK, Jensen ME, Møller M, Le Dous N, Jensen AØ, Zeeman VA, Johannsen CF, Lee A, Thomsen GK, Macoveanu J, Fisher PM, Gillum MP, Jørgensen NR, Bergmann ML, Enghusen Poulsen H, Becker U, Holst JJ, Benveniste H, Volkow ND, Vollstädt-Klein S, Miskowiak KW, Ekstrøm CT, Knudsen GM, Vilsbøll T, Fink-Jensen A. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022 Oct 10;7(19):e159863. doi: 10.1172/jci.insight.159863. PMID: 36066977; PMCID: PMC9675448.
- Nasrollahizadeh A, Kheiri G, Javankiani S, Kheiri S, Hamzavi SF, Karimi M, Amini-Salehi E, Karimi MA. Repurposing GLP-1 receptor agonists for alcohol use disorder: a systematic review and meta-analysis. Diabetol Metab Syndr. 2026 Jan 8;18(1):29. doi: 10.1186/s13098-025-02006-x. PMID: 41508124; PMCID: PMC12825243.
- Patil S, Jha N, Jha MK. Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov. Addict Behav Rep. 2026 Jan 30;23:100671. doi: 10.1016/j.abrep.2026.100671. PMID: 41696398; PMCID: PMC12906085.
- Shevchouk OT, Tufvesson-Alm M, Jerlhag E. An Overview of Appetite-Regulatory Peptides in Addiction Processes; From Bench to Bed Side. Front Neurosci. 2021 Dec 9;15:774050. doi: 10.3389/fnins.2021.774050. PMID: 34955726; PMCID: PMC8695496.
- Elias Wagner, Mikkel Højlund, Jess G Fiedorowicz, René Ernst Nielsen, Søren Dinesen Østergaard, Anne Høye et al. Disparities in diabetes treatment and monitoring for people with and without mental disorders: a systematic review and meta-analysis, Lancet Psychiatry, 2026, 13, 112–124. doi: 10.1016/S2215-0366(25)00332-3.
- Yammine L, de Dios C, Suchting R, Green CE, Nielsen DA, Walss-Bass C, Schmitz JM. Exploring Predictors of Treatment Response to GLP-1 Receptor Agonists for Smoking Cessation. Nicotine Tob Res. 2025 Jun 23;27(7):1294–1300. doi: 10.1093/ntr/ntaf005. PMID: 39780397.
- Yammine L, Green CE, Kosten TR, de Dios C, Suchting R, Lane SD, Verrico CD, Schmitz JM. Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial. Nicotine Tob Res. 2021 Aug 29;23(10):1682–1690. doi: 10.1093/ntr/ntab066. PMID: 33831213; PMCID: PMC8517504.
Language: English
Page range: 5 - 15
Accepted on: Apr 20, 2026
Published on: May 17, 2026
Published by: The Medical Library named after S. Konopka in Warsaw
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Related subjects:
© 2026 Paweł Gwałt, Aleksandra Musioł, Michał Nowakowski, Magdalena Rakuś, Jakub Marzec, Krzysztof Łukasz, published by The Medical Library named after S. Konopka in Warsaw
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.